🇺🇸 FDA

Intelligence · Patent portfolio

Agios Netherlands Patents

Full USPTO pharma patent portfolio for Agios Netherlands — grant dates, expiration, and drug cross-links.

Patents
93
Expiring ≤24m
0

Quick answer

Agios Netherlands has 93 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 2

  1. US 12428376

    Therapeutic compounds and compositions

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12377093

    Pyruvate kinase activators for use in therapy

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11957680

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11919915

    Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11872225

    Pyruvate kinase modulators and use thereof

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11866411

    Therapeutic compounds and compositions

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11793806

    Pyruvate kinase activators for use in therapy

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11590132

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11464775

    Pyruvate kinase modulators and use thereof

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11458127

    Methods of treating brain tumors using combination therapy

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11364240

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11254652

    Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11234976

    Methods of using pyruvate kinase activators

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11040036

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11021515

    Therapeutically active compounds and their methods of use

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10988448

    Therapeutic compounds and compositions

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10980788

    Therapy for treating malignancies

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10946023

    Therapeutically active compounds and their methods of use

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10905692

    Combination therapy for treating malignancies

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10799490

    Pharmaceutical compositions of therapeutically active compounds

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10800782

    Inhibitors of cellular metabolic processes

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10780093

    Methods of treating brain tumors using combination therapy

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10730854

    Therapeutically active compounds and their methods of use

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10717764

    Therapeutically active compounds and their methods of use

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10711314

    Methods for diagnosing IDH-mutant cell proliferation disorders

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10695352

    Combination therapy for treating malignancies

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10689414

    Therapeutically active compounds and their methods of use

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10689375

    Compounds and their methods of use

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10653710

    Combination therapy for treating malignancies

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10640534

    Therapeutically active compositions and their methods of use

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10632114

    Pyruvate kinase activators for use in therapy

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10610125

    Methods and compositions for cell-proliferation-related disorders

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10449184

    Pharmaceutical compositions of therapeutically active compounds

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10434105

    Therapeutically active compounds and their methods of use

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10414740

    Glutaminase inhibitors and method of use

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10376510

    2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10329298

    Inhibitors of cellular metabolic processes

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10294215

    Therapeutically active compounds and their methods of use

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10202339

    Therapeutic compounds and compositions

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10201543

    Therapeutically active compounds and their methods of use

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10188656

    Methods of treatment of malignancies

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10172864

    Therapeutically active compounds and their methods of use

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10137130

    Methods of treatment of malignancies

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10111878

    N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10105369

    Therapeutically active compounds and their methods of use

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10101331

    Methods of evaluating patients using E-cadherin or vimentin

    Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Agios Netherlands have?

93 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Agios Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.